NYSEAMERICAN:CVRS - Corindus Vascular Robotics Stock Price, News & Analysis

Corindus Vascular Robotics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVRS."

Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) announced its quarterly earnings results on Thursday, August, 8th. The medical equipment provider reported ($0.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by $0.01. The medical equipment provider had revenue of $4.58 million for the quarter, compared to analysts' expectations of $4.10 million. View Corindus Vascular Robotics' Earnings History.

Corindus Vascular Robotics is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Corindus Vascular Robotics.

1 brokerages have issued 12 month price targets for Corindus Vascular Robotics' stock. Their predictions range from $4.28 to $4.28. On average, they anticipate Corindus Vascular Robotics' share price to reach $4.28 in the next year. View Analyst Price Targets for Corindus Vascular Robotics.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corindus Vascular Robotics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Corindus Vascular Robotics.

Media stories about CVRS stock have trended positive on Sunday, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Corindus Vascular Robotics earned a coverage optimism score of 2.5 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the immediate future. View News Stories for Corindus Vascular Robotics.

Corindus Vascular Robotics saw a increase in short interest in July. As of July 15th, there was short interest totalling 17,219,500 shares, an increase of 27.2% from the June 15th total of 13,538,800 shares. Based on an average daily trading volume, of 1,890,000 shares, the short-interest ratio is currently 9.1 days. Currently, 16.7% of the shares of the company are short sold. View Corindus Vascular Robotics' Current Options Chain.

Some companies that are related to Corindus Vascular Robotics include Consort Medical (CSRT), Ekf Diagnostics (EKF), Immunodiagnostic Systems (IDH), Theralase Technologies (TLT), Intelligent Ultrasound Group (MED), LiDCO Group (LID), Deltex Medical Group (DEMG), Zecotek Photonics (ZMS), InspireMD (NSPR), Lucid (LCDX), MCP Income Opp Trust Ordinary Units FP (MOT) and Verisante Technology (VRS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Corindus Vascular Robotics investors own include Amarin (AMRN), TransEnterix (TRXC), Advanced Micro Devices (AMD), Micron Technology (MU), Alibaba Group (BABA), NVIDIA (NVDA), Helios and Matheson Analytics (HMNY), Viking Therapeutics (VKTX), TherapeuticsMD (TXMD) and Zynerba Pharmaceuticals (ZYNE).

Corindus Vascular Robotics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.02%), Vanguard Group Inc. (2.56%), Nomura Holdings Inc. (0.50%), Nomura Holdings Inc. (0.50%), Bank of America Corp DE (0.50%) and JPMorgan Chase & Co. (0.38%). Company insiders that own Corindus Vascular Robotics stock include Hudson Executive Capital Lp, Louis A Cannon and Philips Nv Koninklijke. View Institutional Ownership Trends for Corindus Vascular Robotics.

CVRS stock was sold by a variety of institutional investors in the last quarter, including Susquehanna International Group LLP, Nomura Holdings Inc., Nomura Holdings Inc., US Bancorp DE, Commonwealth Equity Services LLC, Bronfman E.L. Rothschild L.P., Bank of America Corp DE and Morgan Stanley. View Insider Buying and Selling for Corindus Vascular Robotics.

CVRS stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., JPMorgan Chase & Co., Jane Street Group LLC, Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., A.R.T. Advisors LLC and Renaissance Technologies LLC. Company insiders that have bought Corindus Vascular Robotics stock in the last two years include Hudson Executive Capital Lp and Louis A Cannon. View Insider Buying and Selling for Corindus Vascular Robotics.

Shares of CVRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CVRS stock can currently be purchased for approximately $4.28.

Corindus Vascular Robotics has a market capitalization of $890.83 million. Corindus Vascular Robotics employs 90 workers across the globe.View Additional Information About Corindus Vascular Robotics.

The official website for Corindus Vascular Robotics is http://www.corindus.com/.

Corindus Vascular Robotics' mailing address is 309 Waverley Oaks Rd Ste 105, WALTHAM, MA 02452-8451, United States. The medical equipment provider can be reached via phone at +1-508-6533335.